A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer

Published:January 10, 2022DOI:


      • Fulvestrant is licensed for the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.
      • One of the largest studied patient cohorts treated with fulvestrant, with data collection from nine UK centres.
      • Results confirm a modest radiological response rate even in a predominantly pretreated cohort.
      • Fair access to fulvestrant monotherapy in England should be standard to enable its use in patients most likely to benefit.



      Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer. The study aim was to analyse demographics and outcomes of UK patients treated with fulvestrant monotherapy at nine representative centres.

      Materials and methods

      Medical records of 459 patients with locally advanced or metastatic ER-positive, HER2-negative breast cancer treated with fulvestrant between August 2011 and November 2018 at nine UK centres were reviewed. Data were collated on demographics, progression-free survival, overall survival and disease response at first radiological assessment following fulvestrant initiation. Patients still alive by December 2018 were censored.


      Data from 429 of the 459 patients identified were eligible for inclusion in the analysis. The median age was 69 (range 21–95) and 64% (n = 275) had Eastern Cooperative Oncology Group performance status 0–1. Bone was the most commonly involved metastatic site (72%, n = 306). However, 295 (69%) patients had visceral involvement. Patients had received a median 2 (range 0–5) prior lines of endocrine therapy and median 0 (range 0–6) prior chemotherapies. Fulvestrant was first-line therapy in 43 patients (10%). The median duration of treatment was 5 months (range 1–88). The median progression-free survival was 5.5 months. In 51% of 350 patients radiologically assessed, there was evidence of disease response to fulvestrant. Fifteen per cent of these had a complete/partial response. Fulvestrant was discontinued predominantly due to disease progression, with 3% discontinued solely due to adverse events. The median overall survival for the whole cohort was 22.5 months (range 0–88).


      This is one of the largest studied cohorts of breast cancer patients treated with fulvestrant. This heavily endocrine-pretreated population reflects real-life use in the UK. Within this context, our retrospective data show that patients can experience maintained disease response when treated with fulvestrant, supporting the importance of equitable availability for all UK patients.

      Key words

      To read this article in full you will need to make a payment


      Subscribe to Clinical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Cancer Research UK. Breast cancer incidence (invasive) statistics. Available at: Accessed 11 April 2021.

        • Iorfida M.
        • Mazza M.
        • Munzone E.
        Fulvestrant in combination with CDK4/6 inhibitors for HER2– metastatic breast cancers.
        Curr Perspect Breast Cancer. 2020; 12: 45-56
        • Di Leo A.
        • Jerusalem G.
        • Petruzelka L.
        • Torres R.
        • Bondarenko I.N.
        • Khasanov R.
        • et al.
        Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
        J Clin Oncol. 2010; 28: 4594-4600
        • Robertson J.F.R.
        • Llombart-Cussac A.
        • Rolski J.
        • Feltl D.
        • Dewar J.
        • Macpherson E.
        • et al.
        Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
        J Clin Oncol. 2009; 27: 4530-4535
        • Robertson J.F.R.
        • Bondarenko I.M.
        • Trishkina E.
        • Dvorkin M.
        • Panasci L.
        • Manikhas A.
        • et al.
        Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
        Lancet. 2016; 388: 2997-3005
        • National Institute for Health and Care Excellence
        Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer.
        2018 (Available at:)
        • Telford C.
        • Bertranou E.
        • Large S.
        • Phelps H.
        • Ekman M.
        • Livings C.
        Cost-effectiveness analysis of fulvestrant 500 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive advanced breast cancer in the UK.
        Pharmacoecon Open. 2019; 3: 559-570
        • Rugo H.S.
        • Dieras V.
        • Cortes J.
        • Patt D.
        • Wildiers H.
        • O'Shaughnessy J.
        • et al.
        Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy – a comparison with MONARCH 1.
        Breast Cancer Res Treat. 2020; 184: 161-172
        • Insa A.
        • Lluch A.
        • Prosper F.
        • Marugan I.
        • Martinez-Agullo A.
        • Garcia-Conde J.
        Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients.
        Breast Cancer Res Treat. 1999; 56: 67-78
        • Fribbens C.
        • O’Leary B.
        • Kilburn L.
        • Hrebien S.
        • Garcia-Murillas I.
        • Beaney M.
        • et al.
        Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer.
        J Clin Oncol. 2016; 34: 2961-2968
        • Zhao Y.
        • Li Y.
        • Gong C.
        • Xie Y.
        • Zhang J.
        • Wang L.
        • et al.
        Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
        Cancer Med. 2020; 9: 8821-8831
        • O'Leary B.
        • Hrebien S.
        • Morden J.P.
        • Beaney M.
        • Fribbens C.
        • Huang X.
        • et al.
        Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
        Nat Commun. 2018; 9: 896
        • National Institute for Health and Care Excellence
        Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negatuive, locally advanced or metastatic breast cancer Technology appraisal guidance [TA495].
        2017 (Available at:)
        • U.S. National Library of Medicine
        A comparative study of AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2).
        2020 (Available at:)
        • Giridhar K.V.
        • Choong G.M.
        • Leon-Ferre R.A.
        • O'Sullivan C.C.
        • Ruddy K.J.
        • Haddad T.C.
        • et al.
        Clinical management of metastatic breast cancer after CDK4/6 inhibitors: a retrospective single-institution study [abstract].
        in: San antonio breast cancer symposium; 2018. SABCS, San Antonio, Texas (TX)2018 (Abstract P6-18-09)
        • Turner N.C.
        • André F.
        • Cristofanilli M.
        • Verma S.
        • Iwata H.
        • Loi S.
        Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3 [abstract].
        in: San antonio breast cancer symposium; 2016. SABCS, San Antonio, Texas (TX)2016 (Abstract P4-22-06)
        • Rugo H.S.
        • Lerebours F.
        • Ciruelos E.
        • Drullinsky P.
        • Ruiz-Borrego M.
        • Neven P.
        • et al.
        Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
        Lancet Oncol. 2021; 22 (Erratum in: Lancet Oncol 2021;22(5):e184): 489-498